SCHEMBL10036037

SCHEMBL10036037

CCN1C(=O)/C(=C\C=C2/Oc3ccccc3N2CC)N(CC)C1=S

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 12/20 0.58
KMT2A Q03164 12/20 0.58
MAPT P10636 12/20 0.58
ALDH1A1 P00352 11/20 0.58
MAPK1 P28482 6/20 0.58
HTT P42858 4/20 0.58
TNNI3 P19429 1/20 0.52
TNNT2 P45379 1/20 0.52
TNNC1 P63316 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
THRB P10828 3/20 0.42
HPGD P15428 3/20 0.42
KDM4C Q9H3R0 2/20 0.42
KDM4E B2RXH2 2/20 0.42
POLB P06746 2/20 0.42
MDM2 Q00987 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
NPC1 O15118 3/20 0.41
RAB9A P51151 2/20 0.41
LMNA P02545 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22906177 1.00 MEN1 (0.58) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL10036043 0.90 MAPT (0.59) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL13067378 0.89 MEN1 (0.58) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL13751809 0.89 ALDH1A1 (0.59) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL14848959 0.89 ALDH1A1 (0.59) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL13026075 0.88 MAPT (0.52) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL6263663 0.87 MEN1 (0.53) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL13026068 0.86 MEN1 (0.51) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL7092891 0.85 MAPT (0.52) MEN1KMT2AMAPTALDH1A1MAPK1
SCHEMBL7050730 0.85 MAPT (0.52) MEN1KMT2AMAPTALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 US disclosed
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 US disclosed
US-20100276670-A1 PHOTOELECTRIC DEVICE, IMAGING DEVICE, AND PHOTOSENSOR FUJIFILM CORPORATION (JP) 2010-11-04 US disclosed
US-20100276670-A1 PHOTOELECTRIC DEVICE, IMAGING DEVICE, AND PHOTOSENSOR FUJIFILM CORPORATION (JP) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT SNCA, PSEN1, CDR2 MEN1 2218/4885KMT2A 2624/4885MAPT 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.